Compare Ascendis Pharma A/S (ASND) vs Western Digital Corp (WDC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Western Digital Corp — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Western Digital Corp trades at $548.53 (market cap $200.81B). The key difference: Western Digital Corp is far larger — about 11.3× Ascendis Pharma A/S's market cap, and Western Digital Corp pays a 0.1% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | WDC | |
|---|---|---|
Market Cap | $17.74B | $200.81B |
Sector | Health | Technology |
52-Week High | $277.18 | $746.23 |
52-Week Low | $163.32 | $66.14 |
Enterprise Value | $18.11B | $199.15B |
Dividend Yield | — | 0.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Western Digital (WDC) trades at $582.59, up 0.78% on the day, with a neutral technical signal and bullish moving averages. The company has beaten EPS estimates for three consecutive quarters, with Q2 2026 expected at $3.29. Strong profitability metrics include a 55.07% net income margin and 37.73% ROE. Recent news highlights AI-driven storage demand and analyst optimism, including a Wells Fargo price target hike on July 10, 2026.
WDC's outlook is positive due to AI infrastructure tailwinds and consistent earnings beats, but risks include sector volatility and premium valuations. The consensus price target of $610.86 suggests modest upside, supported by 72% analyst buy ratings. Investors should monitor execution against growth forecasts and competitive dynamics in the memory market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Western Digital Corp
Western Digital is a vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
Read more on WDC →
